Based on preclinical studies, EMPLICITI directly activates Natural Killer Cells via SLAMF7 and tags myeloma cells for destruction through ADCC1
ADCC=antibody-dependent cellular cytotoxicity; SLAMF7=signaling lymphocytic activation molecule family member 7.
*Extended follow-up analysis through 5 years
HR 0.73; 95% CI, 0.60, 0.87
Primary analysis through 2 years
HR: 0.70; 95% CI, 057, 0.85; P=0.0004
ORR† 78.5% with ERd [95% CI, 73.6, 82.9] vs
65.5% with Rd [95% CI, 60.1, 70.7]; P=0.0002
mPFS 19.4 months with ERd [95% CI, 16.6, 22.2] vs
14.9 months with Rd [95% CI, 12.1, 17.2]1
EMPLICITI with lenalidomide and dexamethasone is
associated with the following Warnings and Precautions:
Infusion Reactions, Infections, Second Primary Malignancies,
Hepatotoxicity, Interference with Determination
of Complete Response, Pregnancy/Females and Males
of Reproductive Potential, and Adverse Reactions.
Please see detailed Important Safety Information below.
for the treatment of multiple myeloma
approved for use in combination with Rd in
patients who have received 1 to 3
In combination with Rd relative to Rd alone, in patients who received 1 to 3 prior therapies,
EMPLICITI IS THE ONLY THERAPY
THAT DEMONSTRATED A
5-YEAR PFS BENEFIT1,6*
the efficacy and safety of EMPLICITI in combination with Rd
in 646 patients (EMPLICITI + Rd, n=321; Rd, n=325) with multiple
myeloma who had received 1 to 3 prior therapies.1
†Assessed by blinded Independent Review Committee per European Group for Blood and Marrow Transplantation (EBMT) response criteria. ORR includes complete response, very good partial response, and partial response.1
ERd=EMPLICITI + lenalidomide + dexamethasone;
Rd=lenalidomide + dexamethasone.